+226.3%
CLSK vs MRNA
+34.8%
+191.4%
-71.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.8% | +5.4% | +1.4% | +6.4% |
| 7D | +7.7% | -1.1% | +8.8% | +7.8% |
| 30D | +12.2% | +126.1% | -113.9% | -3.5% |
| 3M | -15.5% | +190.0% | -205.5% | -34.0% |
| 6M | +39.3% | +157.2% | -117.9% | +12.4% |
| YTD | +35.1% | +388.2% | -353.1% | -11.0% |
| 1Y | +34.0% | +467.0% | -433.0% | -16.2% |
| 3Y | +226.3% | +36.1% | +190.2% | +157.1% |
| All | +226.3% | +34.8% | +191.4% | +157.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling